BBOT Stock Price, Chart, Stats & News
BridgeBio Oncology Therapeutics Inc. (BBOT) does not currently pay a dividend.
BBOT chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -29.90% |
ROE | -65.52% |
D/E | 0.01x |
Interest coverage ratio | – |
BBOT valuation
P/E | – |
P/S | – |
P/B | 0.67x |
P/CF | -2.91x |
P/FCF | -7.44x |
P/OCF | -2.91x |
PEG | 0.06x |
EV multiple | -7.45x |
About
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors.
Similar securities
Based on sector and market capitalization
